Pluri Inc
Company Profile
Business description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Contact
MATAM Advanced Technology Park
Building No. 5
Haifa3508409
ISRT: +972 747108600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
142
Stocks News & Analysis
stocks
Stop asking if there’s a stock market bubble. Ask this instead.
stocks
Are negative AI narratives holding this ASX share back?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,019.50 | 15.80 | -0.17% |
| CAC 40 | 8,367.33 | 17.54 | -0.21% |
| DAX 40 | 24,626.89 | 44.33 | -0.18% |
| Dow JONES (US) | 52,182.74 | 306.63 | 0.59% |
| FTSE 100 | 10,484.22 | 23.80 | -0.23% |
| HKSE | 22,741.82 | 284.86 | -1.24% |
| NASDAQ | 25,820.14 | 522.53 | 2.07% |
| Nikkei 225 | 70,116.82 | 648.71 | 0.93% |
| NZX 50 Index | 13,623.30 | 77.74 | 0.57% |
| S&P 500 | 7,440.43 | 86.41 | 1.18% |
| S&P/ASX 200 | 8,817.90 | 13.60 | -0.15% |
| SSE Composite Index | 4,064.19 | 9.72 | -0.24% |